Patients with multiple myeloma (MM) have experienced a markedly improved survival over the past 25 years, thanks in part to the availability of new drugs [1]. However, a subgroup of patients known as high-risk patients continues to represent an unmet medical need, with an overall survival of less than three years [2]. In the context where we aim to design clinical trials dedicated to high-risk myeloma patients, these patients must be accurately identified from diagnosis. Given the major prognostic role of cytogenetics in myeloma, the Revised International Staging System has included three cytogenetic abnormalities (CA) in 2015: the deletion 17p and the translocations t(4;14) and t(14;16), along with LDH level [3]. The t(14;16) is also considered as a high-risk factor in the m-SMART risk stratification [4]. Whereas le prognostic role of t(4;14) and deletion 17p is widely accepted, the independent prognostic impact of t(14;16) has been a matter of debate [5,6,7,8]. This rare translocation (around 3.5% of MM patients) involves the IGH locus and the oncogene c-MAF, whose overexpression has been shown to mediate innate resistance to proteasome inhibitors [9]. In addition, t(14;16) MM cells clearly display a much higher mutations number and a higher APOBEC-related mutational process than non-t(14;16) MM cells [10, 11].
In this study, we performed targeted next-generation sequencing as previously described [12] on bone marrow CD138-positive sorted cells, obtained in 5141 newly diagnosed myeloma (NDMM) patients. Raw data are available on demand. The Toulouse Ethics Committee approved the study and informed consent was obtained for all included patients. We found a t(14;16) in 169/5141 newly diagnosed patients (3,3%), which was the expected proportion. We observed that t(14;16) was highly associated to other high-risk abnormalities (Fig. 1A). Indeed, 69.2% of patients with t(14;16) also displayed gain/amp 1q vs 29.1% for patients without t(14;16) (P < 0.0001, chi-square test). Patients with t(14;16) also displayed significantly more deletion 1p32 (20.7% vs 8.5%, P < 0.0001), including more biallelic deletion 1p32 (4.7% vs 1.8%, P = 0.013) recently described as a very high-risk entity [12]. A deletion 17p was found in 22.5% of patients with t(14;16), vs 8.7% in patients without t(14;16) (P < 0.0001). We found 8.9% of biallelic inactivation of TP53 in the t(14;16) subgroup, vs 3.1% in the non t(14;16) subgroup (P < 0.0001). Globally, patients with t(14;16) displayed a TP53 mutation in 14.2% of cases, vs 5.5% for non-t (14;16) patients (P < 0.0001). Finally, we compared the proportion of patients with at least two cytogenetic abnormalities among deletion 17p, gain/amp1q, and deletion 1p32. This proportion was 28.4% for patients with t(14;16) vs 6.8% for patients without t(14;16) (p < 0.0001). Only 30/169 t(14;16) patients displayed none abnormality among deletion 17p, TP53 mutation, and chromosome 1 abnormalities.
It has been suggested that patients with t(14;16) were more at risk to have renal impairment [7], that could lead to an underrepresentation of this cytogenetic abnormality in clinical trials. However in this cohort of NDMM patients (not included in clinical trials), those with t(14;16) did not significantly develop more renal failure than other patients (15.4% vs 12.1%, P = 0.3).
Clinical data were available for 2706 NDMM patients (median age 64 years (27–92)) diagnosed between January 2010 and January 2022, followed up for ≥18 months or having died or progressed within 18 months. The median follow-up was 34.6 months. Almost half of the patients (1335) were treated with intensive therapy (classical triplet induction + autologous stem cell transplant, except for 86 patients who received bortezomib-dexamethasone induction, and 194 patients who had anti-CD38 based quadruplet). Half of the non-transplant-eligible patients received lenalidomide + bortezomib + dexamethasone, or lenalidomide + dexamethasone; the other half received an anti-CD38 combined with Lenalidomide and dexamethasone (360 patients) or one of the following combination: bortezomib + cyclophosphamide + dexamethasone or melphalan + prednisone + bortezomib or melphalan + prednisone + thalidomide. Rates of progression-free survival (PFS) and overall survival (OS) were estimated by the Kaplan–Meier method. Tests were two-sided and P<0.05 were considered significant. The median PFS was 24.3 months for the 107 patients with t(14;16) vs 43.9 months for patients without t(14;16) (P < 0.0001). The median OS was 61.3 months for the patients with t(14;16) vs 128.8 months for patients without it (P < 0.0001) (Fig. 1B). Given the high association we found between t(14;16) and deletion 17p, TP53 mutation, gain/amp 1q, and deletion 1p32, we then focused on t(14;16) patients without any of these lesions. PFS and OS were not more significantly shorter than patients without t(14;16) (41.5 and 92.3 months, respectively) (Fig. 1B). Even if the number is very small (only 13 patients from this clinically annotated patient cohort), these data strongly suggest that t(14;16) with no other high-risk lesion may not be considered as a poor factor in MM. Of note, the Revised 2-ISS [13] takes into account 1q gain as a high-risk CA, but not t(14;16). In 2019, the IFM proposed a weighted cytogenetic score [14] notably based on deletion 17p, t(4;14), 1q gain and deletion 1p32, but t(14;16) was not retained in the prognostic model. Of note, in this system, only a deletion 17p was able to confer a poor prognostic by itself, the other lesions had to be combined with each other.
A quite similar situation than for t(14;16) was observed a few years ago with deletion 13q, which has been a quite good surrogate marker for MM high-risk disease, but not an independent factor, since patients with deletion 13q but without deletion 17p nor t(4;14) had similar outcome than patients without deletion 13q [15]. With t(14;16), it is more difficult to address because it is a much rare event whereas deletion 13q is present in about half of NDMM patients.
At this stage, the question was whether t(14;16) assessment is still useful for defining risk in MM. To address this issue, we asked if the presence of a t(14;16) worsen the prognosis of patients presenting a cytogenetic lesion associated to a shorter survival at diagnosis (Fig. 2). For patients with a deletion 17p, the PFS and OS were clearly shorter for those displaying a t(14;16) (13.5 vs 27.4 months, P < 0.0001, and 33.5 vs 62.4 months, P = 0.009, respectively). Although to a lesser extent, the same observation was done for patients with gain/amplification 1q, (PFS 20.5 vs 31.8 months, P = 0.003 and OS 48.2 vs 69.9 months, P = 0.004). Only a tendency was observed for with a deletion 1p32 (PFS 14.6 vs 28.5 months, P = 0.11, and OS 42.4 vs 69.0 months, P = 0.26). These data suggest that the interaction of a t(14;16) with a high-risk cytogenetic lesion can lead to a particularly aggressive disease. The biological mechanism underlying this observation needs to be elucidated.
Our study has several limitations: it is retrospective, treatments are not homogenous, and the cohort size of t(14;16) patients remains small, especially since, by definition, we focused on patients without deletion 17p, TP53 mutation, gain/amp 1q and deletion 1p32.
In conclusion, two third of patients with t(14;16) also display a gain/amp 1q. They also have two to three times more deletion 17p, TP53 mutations and deletion 1p32 than other patients, and almost one-third display at least two of these abnormalities. The t(14;16) has not any prognostic impact if isolated (but numbers are very small). In contrast, its interaction with another prognostic lesion can lead to an aggressive disease. We state that only t(14;16) associated to other high-risk abnormalities should be considered as a high-risk disease in MM.
References
Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10:94.
Davies FE, Pawlyn C, Usmani SZ, San-Miguel JF, Einsele H, Boyle EM, et al. Perspectives on the risk-stratified treatment of multiple myeloma. Blood Cancer Discov. 2022;3:273–84.
Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863–9.
Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88:360–76.
Avet-Loiseau H, Malard F, Campion L, Magrangeas F, Sebban C, Lioure B, et al. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood. 2011;117:2009–11.
Narita T, Inagaki A, Kobayashi T, Kuroda Y, Fukushima T, Nezu M, et al. t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs. Blood Cancer J. 2015;5:e285.
Goldman-Mazur S, Jurczyszyn A, Castillo JJ, Waszczuk-Gajda A, Grzasko N, Radocha J, et al. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. Am J Hematol. 2020;95:503–9.
Mina R, Joseph NS, Gay F, Kastritis E, Petrucci MT, Kaufman JL, et al. Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. Blood Cancer J. 2020;10:40.
Qiang YW, Ye S, Chen Y, Buros AF, Edmonson R, van Rhee F, et al. MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma. Blood. 2016;128:2919–30.
Samur MK, Aktas Samur A, Fulciniti M, Szalat R, Han T, Shammas M, et al. Genome-wide somatic alterations in multiple myeloma reveal a superior outcome group. J Clin Oncol. 2020;38:3107–18.
Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132:587–97.
Schavgoulidze A, Talbot A, Perrot A, Cazaubiel T, Leleu X, Manier S, et al. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor. Blood. 2023;141:1308–15.
D’Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY Project. J Clin Oncol. 2022;40:3406–18.
Perrot A, Lauwers-Cances V, Tournay E, Hulin C, Chretien ML, Royer B, et al. Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma. J Clin Oncol. 2019;37:1657–65.
Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109:3489–95.
Acknowledgements
This work was financially supported by a NIH PO1 grant (NCI P01-155258), a NIH SPORE grant (NCI 5P50CA100707), the Fondation ARC (grant PGA1*20160203788), the Institut National du Cancer (INCA; PLBIO R19-045 and R20-229), the Fondation Toulouse Cancer Santé and IUCT-O translational research program.
Author information
Authors and Affiliations
Contributions
AS, JC, and HA-L designed the research and analyzed the data; JC and HA-L wrote the manuscript, which was reviewed and edited by the other coauthors; LB performed the NGS analysis. All other authors provided study samples and clinical data.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Schavgoulidze, A., Perrot, A., Cazaubiel, T. et al. Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions. Blood Cancer J. 13, 160 (2023). https://doi.org/10.1038/s41408-023-00933-4
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41408-023-00933-4
This article is cited by
-
Translocation t(14;16) in multiple myeloma: gangster or just part of the gang?
Blood Cancer Journal (2024)